JP2010505836A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505836A5
JP2010505836A5 JP2009531440A JP2009531440A JP2010505836A5 JP 2010505836 A5 JP2010505836 A5 JP 2010505836A5 JP 2009531440 A JP2009531440 A JP 2009531440A JP 2009531440 A JP2009531440 A JP 2009531440A JP 2010505836 A5 JP2010505836 A5 JP 2010505836A5
Authority
JP
Japan
Prior art keywords
composition
disease
radiation
cancer
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009531440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/021259 external-priority patent/WO2008060372A2/en
Publication of JP2010505836A publication Critical patent/JP2010505836A/ja
Publication of JP2010505836A5 publication Critical patent/JP2010505836A5/ja
Withdrawn legal-status Critical Current

Links

JP2009531440A 2006-10-04 2007-10-02 ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト Withdrawn JP2010505836A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84928406P 2006-10-04 2006-10-04
PCT/US2007/021259 WO2008060372A2 (en) 2006-10-04 2007-10-02 Thrombin receptor antagonists based on the modified tricyclic unit of himbacine

Publications (2)

Publication Number Publication Date
JP2010505836A JP2010505836A (ja) 2010-02-25
JP2010505836A5 true JP2010505836A5 (https=) 2010-04-22

Family

ID=39284222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531440A Withdrawn JP2010505836A (ja) 2006-10-04 2007-10-02 ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト

Country Status (12)

Country Link
US (1) US20080085923A1 (https=)
EP (1) EP2078012A2 (https=)
JP (1) JP2010505836A (https=)
KR (1) KR20090058583A (https=)
CN (1) CN101553484A (https=)
AR (1) AR063095A1 (https=)
AU (1) AU2007320029A1 (https=)
CA (1) CA2666903A1 (https=)
IL (1) IL198011A0 (https=)
MX (1) MX2009003758A (https=)
TW (1) TW200823206A (https=)
WO (1) WO2008060372A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
ES2437100T3 (es) * 2009-06-04 2014-01-08 Merck Sharp & Dohme Corp. Metabolito activo de un antagonista de los receptores de la trombina
EP2488026A4 (en) * 2009-10-02 2013-04-10 Merck Sharp & Dohme USE OF A PAR-1 ANTAGONIST IN COMBINATION WITH A P2Y12ADP RECEPTOR ANTAGONIST FOR INHIBITING THROMBOSE
CN105777681B (zh) * 2014-12-17 2019-03-01 博瑞生物医药(苏州)股份有限公司 喜巴辛类似物及其中间体的制备方法
WO2016114386A1 (ja) * 2015-01-15 2016-07-21 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患治療剤
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106866450B (zh) * 2017-01-13 2019-01-11 阜阳欣奕华材料科技有限公司 硫酸沃拉帕沙中间体的制备方法
CN110483455A (zh) * 2019-09-29 2019-11-22 天津力生制药股份有限公司 一种硫酸沃拉帕沙中间体醛基物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7304078B2 (en) * 2002-04-16 2007-12-04 Schering Corporation Thrombin receptor antagonists
ES2291323T3 (es) * 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
BR0213967A (pt) * 2001-10-18 2005-08-30 Schering Corp Análogos de himbacina como antagonistas do receptor de trombina

Similar Documents

Publication Publication Date Title
JP2010505836A5 (https=)
HRP20251115T1 (hr) Metode i spojevi za obnavljanje funkcije mutanta p53
AU2019219057B2 (en) FAP inhibitor
JP2009521399A5 (https=)
JP2007523051A5 (https=)
JP7577682B2 (ja) ガレクチン-3の低分子阻害剤
CA2868081C (en) Inhibition of mcl-1 and/or bfl-1/a1
CA2540163A1 (en) Thrombin receptor antagonists
AR080792A1 (es) Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias.
JP2016539121A5 (https=)
JP2010509286A5 (https=)
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
JP2011126896A5 (https=)
JP2018529779A5 (https=)
JP2019504899A5 (https=)
MY140756A (en) Fused azole-pyrimidine derivatives
WO2013048214A3 (en) Novel heterocyclic derivatives and their uses
JP2014012726A5 (https=)
JP2017520613A5 (https=)
JP2017522350A5 (https=)
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
UA101348C2 (ru) 1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеваний
JP2016513704A5 (https=)
RU2014142057A (ru) Комплексная терапия
JP2016529306A5 (https=)